Real‐World Efficacy of Postoperative Adjuvant Nivolumab in High‐Risk Urothelial Carcinoma: A Retrospective Comparative Study in an Asian Population
Asia-Pacific Journal of Clinical Oncology · 2026-10 · 22 (5) · 685-691
DOI: 10.1111/ajco.70051 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 11.11.2025. Verfasst von Ryunosuke Nakagawa und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. Hauptthemen laut MEDLINE: Nivolumab, Antineoplastic Agents, Immunological, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Purpose
To evaluate the real‐world effectiveness of adjuvant nivolumab following radical surgery in patients with high‐risk urothelial carcinoma, using historical data for comparison. Materials and Methods Patients who underwent radical surgery at our institution were retrospectively analyzed. They were divided into two groups: one group received adjuvant nivolumab, and the other received no adjuvant therapy. Oncological outcomes, adverse events, and treatment completion rates were assessed.
Results
A total of 158 patients were included: 20 in the adjuvant nivolumab group and 138 in the control group. The median observation periods were 20.4 months in the nivolumab group and 36.7 months in the control group. The nivolumab group showed significantly improved recurrence‐free survival compared to the control group (hazard ratio: 0.21; 95% confidence interval: 0.10–0.42; p = 0.01). Although overall survival tended to improve in the nivolumab group, the difference was not statistically significant (hazard ratio: 0.32; 95% confidence interval: 0.01–1.01; p = 0.22). Multivariate analysis confirmed adjuvant nivolumab as a significant favorable prognostic factor for recurrence‐free survival (hazard ratio: 0.18; 95% confidence interval: 0.044–0.73; p = 0.017). One‐year treatment was completed in 55.0% of patients. Adverse events led to discontinuation in 25.0%, with major events including interstitial lung disease (three patients), hormonal disorders such as isolated adrenocorticotropic hormone deficiency (2), rash (3), hypothyroidism (1), and hepatitis (1).
Conclusion
Adjuvant nivolumab demonstrated clinical benefit in Asian patients with high‐risk urothelial carcinoma in a real‐world setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Zitieren
APA
Nakagawa, R., Naito, R., Izumi, K., Inaba, T., Toriumi, R., Aoyama, S., Kamijima, T., Kano, H., Makino, T., Kadomoto, S., Iwamoto, H., Yaegashi, H., Kawaguchi, S., Nohara, T., Shigehara, K., & Mizokami, A. (2026). Real‐World Efficacy of Postoperative Adjuvant Nivolumab in High‐Risk Urothelial Carcinoma: A Retrospective Comparative Study in an Asian Population. Asia-Pacific Journal of Clinical Oncology, 22(5), 685-691. https://doi.org/10.1111/ajco.70051
Vancouver
Nakagawa R, Naito R, Izumi K, Inaba T, Toriumi R, Aoyama S, et al. Real‐World Efficacy of Postoperative Adjuvant Nivolumab in High‐Risk Urothelial Carcinoma: A Retrospective Comparative Study in an Asian Population. Asia-Pacific Journal of Clinical Oncology. 2026;22(5):685-691. doi:10.1111/ajco.70051
BibTeX
@article{Nakagawa2026,
author = {Nakagawa, Ryunosuke and Naito, Renato and Izumi, Kouji and Inaba, Takahiro and Toriumi, Ren and Aoyama, Shuhei and Kamijima, Taiki and Kano, Hiroshi and Makino, Tomoyuki and Kadomoto, Suguru and Iwamoto, Hiroaki and Yaegashi, Hiroshi and Kawaguchi, Shohei and Nohara, Takahiro and Shigehara, Kazuyoshi and Mizokami, Atsushi},
title = {Real‐World Efficacy of Postoperative Adjuvant Nivolumab in High‐Risk Urothelial Carcinoma: A Retrospective Comparative Study in an Asian Population},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
volume = {22},
number = {5},
pages = {685--691},
doi = {10.1111/ajco.70051}
}
EUVIMED